Ziccum AB ("Ziccum" or "the Company") announces today, November 11, 2020, that it has received approval for admission to trade on the Nasdaq First North Growth Market. The first day of trading on the Nasdaq First North Growth Market will be December 1, 2020.
Trading in the Company's share on the Spotlight Stock Market will cease and the last day for trading on the Spotlight Stock Market will be November 30, 2020.
Nasdaq's decision is subject to the condition that (i) nothing occurs in connection with the list change that could lead to a different assessment of the stock exchange, (ii) the Company meets the proliferation requirement in accordance with the Nasdaq First North Growth Market Rulebook and that (iii) the Company updates its website in in accordance with the Nasdaq First North Growth Market Rulebook.
The company's share will continue to be traded under the short name ZICC with its current ISIN code SE0011415595. No new shares will be issued in connection with the Company's shares being admitted to trading on the Nasdaq First North Growth Market. The Company's shareholders do not need to take any measures in connection with the list change.
Due to the listing on Nasdaq First North Growth Market, the Company has prepared a company description which is available on Ziccum's website (in Swedish) www.ziccum.com. Ziccum has appointed Erik Penser Bank as the Company's Certified Adviser. The company's legal advisor is Fredersen Advokatbyrå AB.
"The listing on Nasdaq First North Growth Market is a natural step in our ambition for a more international profile and entails better conditions for future value creation for Ziccum's shareholders. Nasdaq is a global and well-known brand that enables increased visibility in the stock market and makes it easier for institutional and international investors to become shareholders in the company." – CEO Göran Conradson.
For more information about Ziccum, please contact:
CEO Ziccum AB
Mob: +46 709 61 55 99
Erik Penser Bank AB
Phone: +46 8-463 83 00
Ziccum develops new thermostable versions of the world's most urgently needed, life-saving vaccines. The Company's patented technology, LaminarPace, enables the production of new, gently air-dried formulations that can be transported easily and cost-effectively, with no need for a costly and complicated cold chain, all the way from the factory to the last child in the last mile of the supply chain.
This is a regulatory press release that was submitted for publication by the company's CEO at 12.30 CET on November 11, 2020.